Clinical Trial Update: Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke [Phase 4]

View source ↗

Summary

Phase 4 trial update on butyphthalide in combination with recombinant tissue plasminogen activator for acute ischemic stroke has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke Ischemic

Drugs mentioned

• butyphthalide (butyphthalide)
• recombinant tissue plasminogen activator (tissue plasminogen activator (rt-PA))

Snippet

Sponsor: Hui-Sheng Chen | Conditions: Stroke, Ischemic | Phase 4 | Status: COMPLETED